SBIR Phase I: Nanotechnology - Nanotexturing of Stents for Improved Performance

SBIR 第一阶段：纳米技术 - 支架纳米纹理以提高性能

• 批准号: 0944979
• 负责人: Rajeev Nair
• 金额: $ 15万
• 依托单位: Photon Energy Technology
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0944979&HistoricalAwards=false
• 关键词: SBIR; Phase; Nanotechnology; Nanotexturing; Stents

This Small Business Innovation Research (SBIR) Phase I project aims to demonstrate a unique and affordable method to nanotexture the surfaces of metal platform drug-eluting stents (DES) using ultrafast laser surface modification. This technology is relatively inexpensive and capable of integrating with laser micromachining that is widely used for the fabrication of DES, thus have advantages over the existing techniques such as self-assembly, imprint lithography, electron beam etc. Laser-nanotextured DES will be evaluated for biocompatibility, absorption, time release and safety profile by in-vitro tests. The broader/commercial impact of this project will be the potential to provide a cost-effective method to nanotexture DES via laser surface modification, which may improve the drug delivery, prevent thrombosis and enhance the safety profile. Although DES has profoundly affected the field of interventional cardiology by dramatically reducing the problem of in-stent restenosis associated with bare metal stent, the adverse long term stent thrombosis raises the question on the safety profile of DES. Laser nanotexturing will add substantial value to stent manufacturing by preventing thrombosis and helping in storage and supply of drugs continuously for a long term.

该小型企业创新研究（SBIR）第一阶段项目旨在展示一种独特且经济实惠的方法，使用超快激光表面改性对金属平台药物洗脱支架（DES）表面进行纳米纹理化。 这种技术相对便宜，并能够与广泛用于DES制造的激光微加工相结合，因此具有优于现有技术，如自组装，压印光刻，电子束等。激光纳米纹理DES将通过体外试验评估生物相容性，吸收，时间释放和安全性。该项目的更广泛/商业影响将是通过激光表面改性提供纳米纹理DES的具有成本效益的方法的潜力，这可能会改善药物递送，预防血栓形成并提高安全性。 尽管DES通过显著减少与裸金属支架相关的支架内再狭窄问题而深刻地影响了介入心脏病学领域，但不良的长期支架内血栓形成引起了对DES安全性的质疑。 激光纳米纹理将通过防止血栓形成和帮助长期持续储存和供应药物来为支架制造增加实质性价值。